Feature | Heart Valve Technology | May 04, 2018| Dave Fornell, Editor

Recent Advances in Transcatheter Valve Technology

An 3D echo view of a Neovasc Tiara transcatheter mitral valve. This valve is currently in clinical trials and is ahead of most of the TMVR devices in development.

A 3-D echo view of a Neovasc Tiara transcatheter mitral valve. This valve is currently in clinical trials and is ahead of most of the TMVR devices in development.

Edwards Lifesciences puchased Valtech to acquire the CardioBand transcatheter annuloplasty system technology. It received market clearance in Europe in April 2018.

Edwards Lifesciences puchased Valtech to acquire the CardioBand transcatheter annuloplasty system technology. It received market clearance in Europe in April 2018.

May 4, 2018 — Transcatheter valve technology has been advancing very quickly and the links to aggregated content from the past year below offer a concise update. Transcatheter aortic valve replacement (TAVR) use has greatly expanded over the past several years. The Boston Scientific Lotus TAVR valve is now positioned to most likely become the third TAVR device available on the U.S. market in the next 18 months. Several transcatheter mitral valve replacement (TMVR) and mitral valve repair technologies are now in clinical trials in the U.S. and overseas. Transcatheter tricuspid valve devices are also now in trials, and a transcatheter tricuspid annual repair device  was just cleared for use in Europe this week. 

Edwards Granted CE Mark For First Transcatheter Tricuspid Therapy

VIDEO: Clinical Outcomes With the Lotus TAVR Valve - interview with Ted Feldman, M.D.

Hospital Consolidation May Increase Access to TAVR, New Cardiac Technologies

VIDEO: Transcatheter Mitral Valve Implantation in Practice and Technologies in Development - Interview with Adam Greenbaum, M.D.

How to Perform Transcaval TAVR Access

VIDEO: How Consolidation Into Larger Health Systems Can Improve Access to TAVR

Boston Scientific Prevails in European Patent Dispute With Edwards Lifesciences

TAVR Can Cause Silent Cerebral Microbleeds, Neurological Impairment

University Hospitals Performs Ohio's First Transcatheter Mitral Valve Replacement

VIDEO: Outcomes Following Urgent TAVR - Results from the TVT Registry - interview with Sammy Elmariah, M.D

Boston Scientific Projects 2019 Launch for Lotus Edge Aortic Valve System

Edwards Completes Enrollment in PARTNER 3 Low-Risk CT Sub-Study

VIDEO: TAVR For Asymptomatic Severe Aortic Stenosis - Interview with Philippe Genereux, M.D.

CoreValve TAVR System Shows Strong Long-Term Performance in Clinical Trials

VIDEO: TAVR for Degenerated Surgical Valves — Valve-in-Valve TAVR Procedures - interview with Sammy Elmariah, M.D

Sentinel Cerebral Protection System Reaches 50-Center Adoption Milestone in U.S.

Edwards Lifesciences Self Expanding TAVR Valve Gains European Approval

Gate Bioprosthesis Used in Canada's First Transcatheter Valve Replacement for Tricuspid Regurgitation

ACC Experts Share What Trends are Ahead in Cardiovascular Medicine in 2018?

Boston Scientific Enters Investment and Acquisition Option Agreement With Millipede

Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System

Enrollment Completed in U.S. IDE Trial for Manta Large Bore Vascular Closure Device

Edwards Acquires Harpoon Medical

VIDEO: Applications in Cardiology for 3-D Printing and Computer Aided Design — interview with Dee Dee Wang, M.D.

4C Medical's Novel Transcatheter Mitral Valve Presented at TCT 2017 Shark Tank Innovation Competition

VIDEO: Cath Lab of the Future Cardiovascular Technologies to Watch — interview with Juan Granada, M.D.

New Analyses Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Aortic Stenosis Patients

VIDEO: MAVERIC 6-month Outcomes for the Arto Mitral Valve Reshaping System

Harpoon Device May Improve Quality, Frequency of Mitral Repair

VIDEO: Update of Mitral Valve Repair and Replacement Technologies - Interview with Ted Feldman, M.D.

Positive, Sustained Improvement at One Year in SCOUT I Transcatheter Tricuspid Repair Trial

Medtronic Unveils Strong Early Outcomes for Intrepid Transcatheter Mitral Valve Replacement System

TAVR Cost-Effective Compared With SAVR in Intermediate-Risk Aortic Stenosis Patients

Sapien 3 Valve Demonstrates Significant Cost Savings Over Surgery In Intermediate-Risk Patients

Second Micro Interventional Devices Annuloplasty System Successfully Implanted

Materialise Announces Start of Pre-Market Phase for Mitral Valve Planning

VIDEO: Transcaval Access in TAVR Procedures - Interview with Adam Greenbaum, M.D.

Claret Medical Closes $14.5 Million in Series C Financing for Sentinel Cerebral Protection System

VIDEO: Conscious Sedation for TAVR Procedures — interview with Mario Goessl, M.D.

Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR

Protembis Announces Successful First-in-Human Use of ProtEmbo Cerebral Protection System in European Trial

Minneapolis Heart Institute Foundation Enrolls First Patient in TRILUMINATE Tricuspid Repair Trial

VIDEO: Mitral and Tricuspid Transcatheter Repair Technologies — interview with Azeem Latib, M.D.

Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System

Transcatheter Mitral Valve Repair Start-up CoreMedic Gets Financing

FDA Expands CoreValve TAVR Valve Use for Intermediate Risk Patients

Mitralign Announces First European Subject Enrolled in SCOUT II Study of Trialign System

BioTrace Medical's Tempo Lead Shows Stability and Safety in Real-World Performance

VIDEO: Transcatheter Tricuspid Valve Repair and Replacement Technologies — interview with Rebecca Hahn, M.D.

FDA Clears First TAVR Embolic Protection System

FDA Clears Aortic, Mitral Valve-In-Valve Procedures for Sapien 3 TAVR Valve

Lotus TAVR System Shows Superior Efficacy to CoreValve in Global REPRISE III Trial

Analysis Looks at Role Type of Valve Plays in Patient Outcomes Post-TAVR

Boston Scientific to Acquire TAVR Maker Symetis

VIDEO: TAVR Stands Equal to Surgical Valve Replacement — interview with Michael Reardon, M.D.

Transcatheter Annuloplasty For Repair Versus Replacement in Functional Mitral Regurgitation

 

Related Content

An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

News | Cath Lab | July 22, 2021
July 22, 2021 — Medis Medical Imaging is partnering with CORRIB Core Lab and Sinomed in randomized clinical trial of
ast End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company's SafeCross Transseptal Radiofrequency (RF) Puncture and Steerable Balloon Introducer System. The 3-in-1 system, which includes a steerable introducer sheath with an ultra-visible positioning balloon and radiofrequency (RF) puncture dilator, aims to provide a predictable and safe solution for electrophysiology (EP) and structural heart interventions requiring left atrial access.
News | Cath Lab | July 14, 2021
July 13, 2021 — East End Medical announced it received U.S.
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone.

Feature | Cath Lab | May 14, 2021 | By Dave Fornell, Editor
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal fun
Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

News | Cath Lab | May 12, 2021
May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has
SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.

Feature | Cath Lab | May 06, 2021 | By Dave Fornell, Editor
April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from
Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria, raising questions about its application in real-world practice. #SCAI2021 Getty Images

Getty Images

News | Cath Lab | May 03, 2021
May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for sta
New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell
News | Cath Lab | April 29, 2021
April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American
There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

News | Cath Lab | April 28, 2021
April 28, 2021 – Results from a retrospective observational study, presented today at...
A cardiac cath lab at Henry Ford Hospital in Detroit. Photo by Dave Fornell

A cardiac cath lab complex PCI case at Henry Ford Hospital in Detroit. Photo by Dave Fornell

News | Cath Lab | April 28, 2021